摘要
目的探索IFN-α(IFN-α)在非典(SARS)、中东呼吸综合征(MERS)和儿童病毒性疾病中的作用,为IFN-α治疗新型冠状病毒肺炎(COVID-19)的临床研究提供一些可借鉴的思路。方法通过检索国内外数据库,获取与IFN-α相关的数据。结果目前尚缺乏IFN-α治疗NCP临床研究数据,IFN-α对SRAS的疗效尚未肯定,对MERS的最佳治疗方法仍未达成共识。但在儿童病毒性疾病中,雾化吸入IFN-α具有作用迅速、疗效可靠、用药剂量小、全身不良反应少等优点,在我国儿童中广泛应用。结论目前尚无NCP的特效药,IFN-α对新冠肺炎的疗效和安全性需要更进一步的临床研究。
OBJECTIVE To explore the role ofα-interferon(IFN-α)in severe acute respiratory syndrome(SARS)、Middle East respiratory syndrome(MERS)and viral diseases of children,in order to provide some useful ideas for clinical study of IFN-αin novel coronavirus pneumonia(COVID-19).METHODS By searching databases at home and abroad,extracted data related with IFN-α.RESULTS Now there was few clinical research data aboutα-interferon in the treatment of NCP.Its effects on SARS had not been confirmed,and there was no consensus on the best treatment of MERS.Aerosol inhalation of IFN-αhad the advantages of rapid action,reliable effect,small dosage,less systemic adverse reactions and so on in children’s viral diseases,and had been widely used.CONCLUSION At present,there were no specific therapeutic drugs.It need more clinical studies on the the efficacy and safety ofα-interferon in NCP.
作者
周花萍
吴红卫
ZHOU Huaping;WU Hongwei(Guangzhou 8th People’s Hospital,Guangzhou,Guangdong 510030,China;The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong 510030,China)
出处
《今日药学》
CAS
2020年第3期157-159,167,共4页
Pharmacy Today
